Condition: Lung Cancer · Sponsor: Galvanize Therapeutics, Inc.
A prospective, single-arm, non-randomized, single-center, open-label, treat and resect study following patients through surgical resection. The study is designed to evaluate the safety and feasibility of the Aliya EX System for the ablation of pulmonary lesions using pulsed electric field (PEF) energy delivery. The study is intended for adult patients with suspected or confirmed pulmonary malignant lesion(s) ≥1.5 cm to ≤4 cm whom are surgical candidates and have not received treatment for the index tumor in the last two years.
This description comes directly from the study's public registry record.
Maria Plentl, MSN · (650) 268-4252 · mplentl@galvanizetx.com
Partha Seshaiah, PhD · (650) 268-4252 · pseshaiah@galvanizetx.com
Always discuss trial participation with your own doctor first.
| Prince of Wales Hospital | Shatin, Hong Kong | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07487064